After halting development of the Phase III breast and lung cancer treatment iniparib in June because of lack of efficacy, Sanofi is pinning its near-term oncology hopes on fedratinib, a JAK2 inhibitor for myelofibrosis and the sole remaining oncology asset in Phase III.
Fedratinib could represent an important turning point for Sanofi’s oncology portfolio, which is largely made up of mature
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?